Actuate Therapeutics ACTU

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
-$0.09 (-1.30%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

Relative Strength Index (RSI)

- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

- The RSI is calculated using the following formula:

RSI = 100 - (100 / (1 + RS))

Where RS is the ratio of the average gains to the average losses over a specified period.

- The default time period used is 14 days.

- RSI values range between 0 and 100.

RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

About

Business overview of Actuate Therapeutics (ACTU)
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3β, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.

Key Insights

Critical company metrics and information

  • Latest Closing Price

    $6.95

  • Market Cap

    $135.74 Million

  • Price-Earnings Ratio

    -12.64

  • Total Outstanding Shares

    19.53 Million Shares

  • Dividend

    No dividend

  • IPO Date

    August 13, 2024

  • SIC Description

    Pharmaceutical Preparations

  • Primary Exchange

    NASDAQ

  • Type

    Common Stock

  • Headquarters

    1751 river run, Fort worth, TX, 76107

  • Homepage

    https://www.actuatetherapeutics.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

July 1, 2024 to September 30, 2024
MetricValue
Net Cash Flow$0
Net Cash Flow From Operating Activities$-9.15 Million
Net Cash Flow From Investing Activities$-13.17 Million
Net Cash Flow, Continuing$0
Net Cash Flow From Financing Activities$22.32 Million
Net Cash Flow From Operating Activities, Continuing$-9.15 Million

Income Statement

July 1, 2024 to September 30, 2024
MetricValue
Preferred Stock Dividends And Other Adjustments$0
Net Income/Loss Available To Common Stockholders, Basic$-5.97 Million
Income/Loss From Continuing Operations After Tax$-5.97 Million
Nonoperating Income/Loss$-578,058
Other Operating Expenses$1.64 Million
Basic Average Shares$10.77 Million

Comprehensive Income

July 1, 2024 to September 30, 2024
MetricValue
Other Comprehensive Income/Loss$0
Comprehensive Income/Loss$-5.97 Million
Comprehensive Income/Loss Attributable To Noncontrolling Interest$0
Comprehensive Income/Loss Attributable To Parent$-5.97 Million

Balance Sheet

July 1, 2024 to September 30, 2024
MetricValue
Current Assets$14.26 Million
Temporary Equity$0
Assets$14.26 Million
Liabilities And Equity$14.26 Million
Noncurrent Liabilities$406,683
Liabilities$8.90 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends

Recent Headlines From The Web

Latest news, press releases, and media coverage about ACTU from trusted financial sources
    All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

    ⓒ 2025 Financhle. All Rights Reserved.